191 related articles for article (PubMed ID: 34231135)
21. Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries.
Morel T; Arickx F; Befrits G; Siviero P; van der Meijden C; Xoxi E; Simoens S
Orphanet J Rare Dis; 2013 Dec; 8():198. PubMed ID: 24365263
[TBL] [Abstract][Full Text] [Related]
22. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
23. Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Walton M; Sharif S; Simmonds M; Claxton L; Hodgson R
Pharmacoeconomics; 2019 Oct; 37(10):1209-1217. PubMed ID: 30982165
[TBL] [Abstract][Full Text] [Related]
24. The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy.
Xoxi E; Facey KM; Cicchetti A
Front Pharmacol; 2021; 12():699466. PubMed ID: 34456724
[TBL] [Abstract][Full Text] [Related]
25. Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis.
Vreman RA; Broekhoff TF; Leufkens HG; Mantel-Teeuwisse AK; Goettsch WG
Int J Environ Res Public Health; 2020 Nov; 17(22):. PubMed ID: 33182732
[TBL] [Abstract][Full Text] [Related]
26. Determinants of Managed Entry Agreements in the context of Health Technology Assessment: a comparative analysis of oncology therapies in four countries.
Efthymiadou O; Kanavos P
Int J Technol Assess Health Care; 2021 Jan; 37():e31. PubMed ID: 33509311
[TBL] [Abstract][Full Text] [Related]
27. Health technology assessment criteria as drivers of coverage with managed entry agreements: a case study of cancer medicines in four countries.
Efthymiadou O
Eur J Health Econ; 2023 Sep; 24(7):1023-1031. PubMed ID: 36219363
[TBL] [Abstract][Full Text] [Related]
28. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.
Garrison LP; Towse A; Briggs A; de Pouvourville G; Grueger J; Mohr PE; Severens JL; Siviero P; Sleeper M
Value Health; 2013; 16(5):703-19. PubMed ID: 23947963
[TBL] [Abstract][Full Text] [Related]
29. Health technology assessment in Australia: a role for clinical registries?
Scott AM
Aust Health Rev; 2017 Mar; 41(1):19-25. PubMed ID: 27028134
[TBL] [Abstract][Full Text] [Related]
30. Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future.
Pauwels K; Huys I; Vogler S; Casteels M; Simoens S
Front Pharmacol; 2017; 8():171. PubMed ID: 28420990
[No Abstract] [Full Text] [Related]
31. Clinical guidelines and payer policies on fusion for the treatment of chronic low back pain.
Cheng JS; Lee MJ; Massicotte E; Ashman B; Gruenberg M; Pilcher LE; Skelly AC
Spine (Phila Pa 1976); 2011 Oct; 36(21 Suppl):S144-63. PubMed ID: 21952186
[TBL] [Abstract][Full Text] [Related]
32. Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries.
Angelis A; Lange A; Kanavos P
Eur J Health Econ; 2018 Jan; 19(1):123-152. PubMed ID: 28303438
[TBL] [Abstract][Full Text] [Related]
33. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
34. Public sector reforms and their impact on the level of corruption: A systematic review.
Mugellini G; Della Bella S; Colagrossi M; Isenring GL; Killias M
Campbell Syst Rev; 2021 Jun; 17(2):e1173. PubMed ID: 37131927
[TBL] [Abstract][Full Text] [Related]
35. Mortality and Morbidity Effects of Long-Term Exposure to Low-Level PM
Brunekreef B; Strak M; Chen J; Andersen ZJ; Atkinson R; Bauwelinck M; Bellander T; Boutron MC; Brandt J; Carey I; Cesaroni G; Forastiere F; Fecht D; Gulliver J; Hertel O; Hoffmann B; de Hoogh K; Houthuijs D; Hvidtfeldt U; Janssen N; Jorgensen J; Katsouyanni K; Ketzel M; Klompmaker J; Hjertager Krog N; Liu S; Ljungman P; Mehta A; Nagel G; Oftedal B; Pershagen G; Peters A; Raaschou-Nielsen O; Renzi M; Rodopoulou S; Samoli E; Schwarze P; Sigsgaard T; Stafoggia M; Vienneau D; Weinmayr G; Wolf K; Hoek G
Res Rep Health Eff Inst; 2021 Sep; 2021(208):1-127. PubMed ID: 36106702
[TBL] [Abstract][Full Text] [Related]
36. Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?
Jommi C; Addis A; Martini N; Nicod E; Pani M; Scopinaro A; Vogler S
Glob Reg Health Technol Assess; 2021; 8():114-119. PubMed ID: 36627869
[TBL] [Abstract][Full Text] [Related]
37. Drug treatment for spinal muscular atrophy type I.
Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD006281. PubMed ID: 31825542
[TBL] [Abstract][Full Text] [Related]
38. TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases.
Annemans L; Makady A
Orphanet J Rare Dis; 2020 May; 15(1):127. PubMed ID: 32456653
[TBL] [Abstract][Full Text] [Related]
39. Financing and Reimbursement of Approved Advanced Therapies in Several European Countries.
Iglesias-López C; Agustí A; Vallano A; Obach M
Value Health; 2023 Jun; 26(6):841-853. PubMed ID: 36646280
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
